Showing results (71-80 of 172) with videos related to

Sort By:
Pageof 18
Analytical Methods : Advancing Methods and Applications|November 8, 2023
Detection of coca alkaloids in oral fluid from coca leaf (tea) consumers: using solid phase extraction to improve validation parameters and widen the detection windowI Álvarez-Freire, P Cabarcos-Fernández, N C Rubio, et al.
Actas Urologicas Espanolas|September 18, 2009
[Laparoscopic radical nephrectomy in big surgical specimens]Sergio Alonso y Gregorio, S Sánchez, C Soler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2013
HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximabF Sclafani, A Roy, D Cunningham, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 23, 2016
Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trialF Longo-Muñoz, G Argiles, J Tabernero, et al.
ESMO Open|September 15, 2022
Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumorsC Le Tourneau, H Becker, R Claus, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 20, 2009
Consensus on the treatment of pancreatic cancer in SpainM Hidalgo, A Abad, E Aranda, et al.
ESMO Open|August 13, 2025
Differentiating low tumor burden from oligometastatic disease in colorectal cancer: a call for individualized therapeutic approachesM C de Grandis, I Baraibar, O Prior, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017
ESMO-Magnitude of Clinical Benefit Scale version 1.1N I Cherny, U Dafni, J Bogaerts, et al.
British Journal of Cancer|May 20, 2015
Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancerT Macarulla, A Cervantes, J Tabernero, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 15, 2014
TTD consensus document on the diagnosis and management of exocrine pancreatic cancerM Benavides, A Abad, I Ales, et al.
Pageof 18